Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lipson

Showing results (131-140 of 205) with videos related to

Pageof 21
Sort By:
Journal for Immunotherapy of Cancer|October 12, 2018
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesKendall F Moseley, Jarushka Naidoo, Clifton O Bingham, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.
Molecular Oncology|August 17, 2018
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingSteven P Rowe, Brandon Luber, Monique Makell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2012
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyEvan J Lipson, William H Sharfman, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody ComparisonJoel C Sunshine, Peter L Nguyen, Genevieve J Kaunitz, et al.
Cancer Immunology Research|January 14, 2014
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survivalEvan J Lipson, Jeremy G Vincent, Myriam Loyo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of responseJ E Stein, A Soni, L Danilova, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabLaura C Cappelli, Anna Kristina Gutierrez, Alan N Baer, et al.
The British Journal of Dermatology|July 27, 2025
Merkel Cell Carcinoma in Solid Organ Transplant Recipients: Prognosis and Response to ImmunotherapyTomoko Akaike, Peter Y Ch'en, Daniel S Hippe, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Pageof 21

Showing results (131-140 of 205) with videos related to

Sort By:
Pageof 21
Journal for Immunotherapy of Cancer|October 12, 2018
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case seriesKendall F Moseley, Jarushka Naidoo, Clifton O Bingham, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.
Molecular Oncology|August 17, 2018
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingSteven P Rowe, Brandon Luber, Monique Makell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2012
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyEvan J Lipson, William H Sharfman, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody ComparisonJoel C Sunshine, Peter L Nguyen, Genevieve J Kaunitz, et al.
Cancer Immunology Research|January 14, 2014
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survivalEvan J Lipson, Jeremy G Vincent, Myriam Loyo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of responseJ E Stein, A Soni, L Danilova, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabLaura C Cappelli, Anna Kristina Gutierrez, Alan N Baer, et al.
The British Journal of Dermatology|July 27, 2025
Merkel Cell Carcinoma in Solid Organ Transplant Recipients: Prognosis and Response to ImmunotherapyTomoko Akaike, Peter Y Ch'en, Daniel S Hippe, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Pageof 21